Compare IDN & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | RPTX |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.6M | 92.4M |
| IPO Year | 1999 | 2020 |
| Metric | IDN | RPTX |
|---|---|---|
| Price | $6.88 | $2.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $7.33 | $3.00 |
| AVG Volume (30 Days) | 194.8K | ★ 530.7K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $21,968,000.00 | $11,870,000.00 |
| Revenue This Year | $12.25 | N/A |
| Revenue Next Year | $11.20 | $9.55 |
| P/E Ratio | $666.09 | ★ N/A |
| Revenue Growth | ★ 14.20 | N/A |
| 52 Week Low | $2.17 | $0.89 |
| 52 Week High | $7.48 | $2.30 |
| Indicator | IDN | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 55.66 |
| Support Level | $6.25 | $2.11 |
| Resistance Level | $7.06 | $2.27 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 79.18 | 28.13 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.